ADDITIONAL COMMONWEALTH SUPPORT TO PROTECT HEALTHCARE WORKERS FROM COVID-19

[vc_row][vc_column][vc_column_text]From this week, three new measures will be introduced to help all states and territories learn from what has occurred in Victoria and new information from around the world.

Firstly, a new partnership has been established between the Infection Control Expert Group (ICEG) and the National COVID-19 Evidence Taskforce led by the Living Guidelines Consortium.

With so much evidence emerging so quickly, this partnership will bring together Australia’s leading infection control practitioners, many of whom are frontline clinicians, with other senior healthcare workers, to review the latest evidence on infection prevention and control during COVID-19.

The partnership will contribute to national infection control guidance by providing consensus guidelines on specific infection control issues that have emerged during COVID-19.

Secondly, the AHPPC has endorsed an expansion of national surveillance of healthcare worker infection to ensure we have a better understanding of COVID-19 among healthcare workers at the state and territory level.

This will provide more information on the type of healthcare workers who are becoming infected and enable state and territory governments to target their investigations and interventions based on national-level data.

Thirdly, the Australian Government has funded a new network of epidemiologists – or “disease detectives”. These ‘COVID-NET’ epidemiologists will be available on request by state and territory public health units to assist investigating healthcare worker outbreaks. They will also gather and analyse data on healthcare worker infection at a national level.

The Government says it is committed to assisting the states and territories to understand where workplace controls designed to protect healthcare workers have can further strengthened. It is important healthcare facilities to continue to review their controls and strengthen these to ensure workers are better protected.

The Australian Government is continuing to support hospitals in their efforts to protect their workers from COVID-19. This includes the provision of vital personal protective equipment, drawn from the National Medical Stockpile.

Since March, over 73 million masks have been dispatched from the National Medical Stockpile to support healthcare workers, aged care workers, States and Territories and to support the disability sector.

Australia’s healthcare workers are doing an outstanding job of bravely caring for the health and wellbeing of Australians who have either contracted – or are suspected to have contracted – COVID-19.

They are at the frontline of our fight against COVID-19 and deserve the greatest possible protection from contracting the virus themselves.[/vc_column_text][/vc_column][/vc_row]

AUSTRALIAN MADE NASAL SWAB KITS FOR COVID-19 TESTING

[vc_row][vc_column][vc_column_text]3DMeditech will supply Australian made, 3D printed nasopharyngeal swab kits. The kits will be issued from the stockpile to general practitioners, private pathology providers and state and territory governments according to their need for ongoing coronavirus testing.

The kits will include a nasopharyngeal swab, viral transport “media” (CDC-prescribed viral transport medium), and a bio hazard bag.

The swabs are the first sterile 3D printed swabs to be included on the Australian Register of Therapeutic Goods.

The kits will make it easy and safe for healthcare professionals to collect clinical specimens from people presenting for COVID-19 testing, and for the samples to be transported to testing laboratories.

3DMeditech, based in Port Melbourne, will deliver the first swabs this week, with further deliveries continuing weekly until early March 2021.

The National Medical Stockpile is a strategic reserve of personal protective equipment (PPE) and medicines maintained by the Australian Government for use in a public health emergency, such as the current pandemic.

Finding an Australian supplier of sterile nasal swabs is another positive move for the nation’s health security. Reliance on overseas suppliers can make it difficult to source vital health resources, such as virus testing materials and PPE, when global demand is high.

In recent weeks, the Government has signed major agreements worth over $1.7 billion to ensure Australia can mass produce vital vaccines, including a COVID-19 vaccine.

The production and supply agreements that form part of the Government’s COVID-19 response plan, means Australians will be among the first in the world to receive a vaccine, after trials have proven it to be safe and effective.[/vc_column_text][/vc_column][/vc_row]

LOCALLY MADE LIFESAVING VENTILATORS

[vc_row][vc_column][vc_column_text]At the height of the pandemic, NSW Premier, Gladys Berejiklian, appealed to businesses to pivot their focus to producing critical medical supplies in the fight against COVID-19.

The Premier said that global supply chains were disrupted, but thanks to local universities and manufacturers stepping up, they were able to join forces to develop prototype ventilators.

“Two ventilators are on track to receive regulatory approval within weeks and, if needed, can be produced for hospitals here and potentially overseas, saving lives and boosting jobs,” Ms Berejiklian said.

The Ventilator Innovation Project was part of the NSW Government’s $800 million investment to help increase services and equipment to combat COVID-19.

The NSW Government knows that having access to a ventilator can be the difference between life and death for severe COVID cases, which have become all too apparent in situations overseas.

In some of the worst-hit nations, health staff were forced to limit who could access ventilators – a situation the Government says is why NSW needs reliable local supply chains to safeguard patients.

Minister for jobs, Investment, Tourism and Western Sydney, Stuart Ayres, said the pandemic had inspired a wave of innovation and rapid development across the globe, and local manufacturers and universities had risen to the challenge.

“One thing history has shown us is that crises stimulate innovation and this pandemic has provided an environment for launching and testing new ideas,” Mr Ayres said.

“We congratulate the successful teams behind the CoVida Ventilator, led by the University of Sydney, with clinicians at Westmead and Royal North Shore Hospitals, and Ventasys, developed by AmpControl with clinicians at the John Hunter Hospital.”[/vc_column_text][/vc_column][/vc_row]

HUNT ANNOUNCES $16.9 MILLION FOR HEALTH AND MEDICAL RESEARCH

[vc_row][vc_column][vc_column_text]In a statement announcing the investment, Minister for Health, Greg Hunt, confirmed more than $16.9 million had been awarded to researchers to study women’s health issues and aspects of primary health care, and to facilitate more and better clinical trials of new and improved treatments.

In the lead up to Women’s Health Week – taking place from 7th to 11th September 2020 – the MRFF grants announced would include:

  • $5 million over five years for the National Women’s Health Research, Translation and Impact Network, aimed at research with strong potential to improve health outcomes for women and girls;
  • $5 million over four years to the Australian Clinical Trials Alliance to be a national partner providing specialised leadership and support to both investigator-led and industry clinical trials, and to Clinical Quality Registries; and
  • More than $6.9 million delivered to five projects to improve primary health care in the areas of contraception and abortion for rural women, health care for people in aged care, diabetes in Indigenous Australians, nutrition and heart disease, and the health of urban Indigenous people.

Compared with men, women have a higher life expectancy but experience more disease burden from living with disease, rather than dying early from disease and injury.

The Women’s Health Network are expected to use the funding for research into nine priority areas, including reproductive health, mental health, and preventing cancer and heart disease.

The Government has said the project will also boost national and international collaboration on women’s health, build health workforce capacity and develop leaders in women’s health.

In addition to these grants, Minister Hunt said he was announcing new grant opportunities worth more than $86.5 million for clinical trials and other vital research.

Clinical trial grant opportunities totally $77.2 million will provide up to:

  • $24 million for the Million Minds Mission Mental Heath Research supporting access to new approaches to prevention, diagnoses, treatment and recovery;
  • $3 million for clinical trials to examine the benefits of medicinal cannabis for managing pain, symptoms and aside effects for cancer patients;
  • $25.2 million for international clinical trial collaborations; and
  • $25 million for clinical trials of new or improved treatments for rare cancers, rare diseases and other illness with unmet clinical need.

Other grant opportunities are making $9.3 million available for research:

  • $4.8 million for primary health care research; and
  • $4.5 million from the MRFF and National Health and Medical Research Council for research into silicosis, a preventable lung disease related to inhalation of fine silica dust from artificial stone bench tops.

The Government has identified investment in health and medical research as one of its key priorities in its Long Term National Health Plan.[/vc_column_text][/vc_column][/vc_row]

TELEHEALTH, E-PRESCRIBING ARRANGEMENTS MUST BE EXTENDED

[vc_row][vc_column][vc_column_text]The Select Committee on Financial Technology and Regulatory Technology has made the recommendations in its interim report.

“The AMA has long advocated for Medicare-subsidised telehealth consultations, and temporary Medicare COVID-19 arrangements have shown the value of telehealth,” AMA President, Dr Omar Khorshid, said today.

“The telehealth items have supported the provision of care during these very difficult times, and have been embraced by patients and doctors.

“The AMA is in discussions with the Commonwealth Government about the long-term future of Medicare-funded telehealth for patients who need to see their GP or non-GP specialist.

“This is an ongoing piece of work. In the meantime, the AMA has called for the extension until March next year of the temporary telehealth items, which are due to expire at the end of this month.

“While work on e-prescribing is progressing very quickly, it is still in a limited testing phase. We welcome the Government’s commitment to its roll-out and want to see the extension of temporary COVID-19 arrangements that have allowed pharmacists to dispense medication using a digital image of a prescription.

“With Australia still in the midst of a global pandemic, these temporary arrangements must continue. They are essential to efforts to contain the spread of the virus.

“The AMA is keen to see the Government make a decision on the extension of these temporary arrangements as soon as possible. Practices are already taking appointments for October and beyond.

“Practices and patients alike need certainty about the availability of telehealth, particularly for vulnerable patients.”[/vc_column_text][/vc_column][/vc_row]

NOMINATIONS OPEN FOR THE AUSTRALIAN MEDTECH INDUSTRY AWARDS

[vc_row][vc_column][vc_column_text]Setup by the MTAA, the Australian MedTech Industry Awards are the industry’s premier awards event, recognising outstanding individuals and organisations across Australia.

For this year’s awards, MTAA said they are establishing a new award to be called the Women in MedTech Award for Emerging Women in Leadership.

MTAA has championed the push to better engage and encourage women into the medical technologies professions through the establishment of its Women in MedTech initiative.

Leading the debate and promoting the benefits of more women in the workplace MTAA and its members companies continue its proactive support of gender diversity, investing in women in MedTech to unlock their full potential.

The award categories are:

KERRIN RENNIE AWARD

The Kerrin Rennie Award for Excellence in Medical Technology – Improving Quality of Life was established to recognise and profile the innovative and extraordinary contribution of medical technology to improving health outcomes of Australian patients.

The Award was inaugurated in 2007 and is endowed by the Rennie family in memory of Kerrin, a long serving and highly respected member of the Australian medical technology community.

OUTSTANDING ACHIEVEMENT AWARD

This award recognises an individual who has contributed in an exceptional way to the medical technology industry in Australia. This may be evidenced through their contribution to industry development, improvement in patient outcomes or excellence in leadership or innovation.

WOMEN IN MEDTECH AWARD (INDIVIDUAL AND COMPANY)

MTAA introduced the Women in MedTech Awards in 2017. The Awards are presented to both an individual and a company who have been leaders in advancing or achieving a significant result in the WiMT mission or goals within their company or the industry.

WOMEN IN MEDTECH EMERGING WOMEN IN LEADERSHIP

MTAA is  introducing the Women in MedTech Award for Emerging Women in Leadership this year. This Award celebrates inspiring emerging female leader in the medical technology industry. This is exclusively for MTAA members only.

Nominations close 22 October 2020, and winners announced on 17 November 2020.[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column width=”1/4″][/vc_column][vc_column width=”1/2″][vc_btn title=”CLICK TO NOMINATE” color=”primary” size=”lg” align=”center” link=”url:https%3A%2F%2Fwww.mtaa.org.au%2Faustralian-medtech-industry-awards|||”][/vc_column][vc_column width=”1/4″][/vc_column][/vc_row]

NEW PRIORITY MIGRATION LIST ANNOUNCED

[vc_row][vc_column][vc_column_text]The Government has identified 17 occupations on the Priority Migration Skilled Occupation List (PMSOL), confirming they were chosen based on advice from the National Skills Commission and consultation with relevant Commonwealth agencies. The list is expected to be reviewed regularly.

Acting Minister for Immigration, Citizenship, Migrant Services and Multicultural Affairs, Alan Tudge, said the changes would strike the right balance for Australia’s economic recovery.

“Our priority is getting Australians back into work but we also need key health workers to help fight the virus and skilled migrants who are going to be job multipliers, to help the economy recover,” Mr Tudge said.

“These occupations in the health care, construction and IT sectors will supercharge both our health and economic response to COVID-19.

“Visa holders who have been sponsored by an Australian business in a PMSOL occupation can request an exemption from Australia’s travel restrictions, but will be subject to a strict 14 days quarantine on arrival at their own expense.”

While existing skilled migration occupation lists will remain active and visas will still be processed, priority will be given to those in occupations on the PMSOL.

The 17 occupations (ANZSCO code) on the list are:

  • Chief Executive or Managing Director
  • Construction Project Manager
  • Mechanical Engineer
  • Resident Medical Officer
  • Psychiatrist
  • Medical Practitioner nec
  • Midwife
  • Registered Nurse (Aged Care)
  • Registered Nurse (Critical Care and Emergency)
  • Registered Nurse (Medical)
  • Registered Nurse (Mental Health)
  • Registered Nurse (Perioperative)
  • Registered Nurses nec
  • Developer Programmer
  • Software Engineer
  • Maintenance Planner

PulseLine advises readers seeking further information about the travel exemption process for those critical skills and sectors, please visit: https://covid19.homeaffairs.gov.au/critical-skills-and-sectors[/vc_column_text][/vc_column][/vc_row]

RAMSAY CALLS FOR CORPORATE INSUERS TO PASS ON GAINS

[vc_row][vc_column][vc_column_text]Australian healthcare company, Ramsay Health Care, has called on corporate health insurers to pass on the more than $1 billion in gains back to communities.

In a story covered by The Australian, Ramsay Health Care’s chief executive, Craig McNally, discussed the healthcare provider’s $284 million fall in net profit, which has been impacted greatly due to the COVID-19 pandemic.

Despite the sizable impact the pandemic has had on Ramsay Health Care and other health providers, corporate health insurers have continued to rake in profits during the elective surgery hibernation period.

To help mask the appearance of their profits during the pandemic, corporate health insurers have decided to bring forward “deferred claims” totalling $1.4 billion, which, thanks to clever accounting, reduced their reportable profits, despite elective surgery claims being suspended.

Data released by the Australian Prudential Regulatory Authority (APRA) revealed that during the pandemic corporate health insurers have raked in gross mega-COVID-profits of $1.03 billion, while cutting the actual benefits paid to policy holders to $20.3 billion, down $600 million from 2019.

Mr McNally said the APRA data shows corporate health insurers have saved over $1 billion in claims costs for the last quarter.

“Their windfall gains put them in a very strong financial position and it would be unreasonable of them not to look at what the broader impact on the system is,” Mr McNally told The Australian.

The relationship between corporate health insurers and others in the health sector have become increasingly tense. As many health industries have continued to make cuts to support the Government’s COVID-19 response, impacting their bottom lines, the private health insurance industry has been accused of profiteering on the back of the once-in-a-generation health crisis.

The association representing medical technology innovators, MTAA, has also called out the corporate insurers, urging them to reverse their premium increases and return windfall profits to their customers.

“If private health insurers in Ireland, and even car insurers in Australia, can return premiums to their customers in this crisis, why can’t corporate health insurers give back some of their windfall profits to struggling Australian families? Why can’t they put people before profits?” Mr Burgess asked.

Many in the health sector will be keeping a keen eye on corporate health insurers to make sure their customers will actually receive the value for these deferred claims.[/vc_column_text][/vc_column][/vc_row]

Aussie company accelerates global ventilator knowledge to help address global demand

[vc_row][vc_column][vc_column_text]These Jigs reduce the time it takes manufacturers to learn how to assemble, operate and maintain the ventilator specifications provided through the blueprints – an important consideration given the global ventilator demand and the complexity of the technology.

According to CEO and co-founder of JigSpace, Zac Duff: “What we saw with the public sharing of the ventilator design specifications was that for rapid ventilator manufacturing at scale, manufacturers needed a consistent 3D knowledge sharing solution. Our goal was to transfer knowledge as quickly as possible to help doctors and patients dealing with COVID-19. Since developing the technology, we have seen companies like Tesla and Mayo Clinic use our platform.”

The 3D Jigs are viewed in augmented reality via an iPhone or iPad and allow manufacturing or healthcare partners to visually guide themselves through assembling specific components or operations in-situ with their relevant factory, lab or work environments.

“We understand the urgent need, across the globe, for ventilators as a life-saving device in the management of COVID-19 patients,” said Liz Carnabuci, vice president, Medtronic Australasia. “No single company can meet the global ventilator demand alone. We are pleased to work with JigSpace to increase global ventilator manufacturing capabilities.”

About 7,000 manufacturers who downloaded Medtronic’s PB560 design plans are now using or going to use various AR training guides in Jig Workshop, with part of this success down to an easily accessible app, and not requiring additional hardware, unlike other expensive technologies. This has led to extensive usage in developing countries, as well as traditional manufacturing centres in OECD countries.

Says Mr Duff: “We are seeing a maturation of how AR technology is applied due to COVID-19. Typical knowledge transfer processes have proved to be brittle in this new environment. JigSpace represents the future of how durable manufacturers collaborate, adapt and scale up complex supply chains.”[/vc_column_text][/vc_column][/vc_row]

Boost Primary Care To Help Patients In Need

[vc_row][vc_column][vc_column_text]In December 2019, the RACGP released its 2020-21 federal pre-budget submission. Following policy and funding decisions in response to the COVID-19 pandemic, the RACGP has raised matters for urgent consideration in its 2020-21 pre-budget update submission.

The RACGP has called on government to:

  • extend Medicare subsidies for telehealth and telephone consultations beyond 30 September
  • implement voluntary patient enrolment to enhance continuity of care
  • help GPs care for patients with chronic and complex conditions via longer consultations
  • provide additional Medicare subsidies for mental health RACGP spokesperson Dr Bruce Willett said that now was the right time to give general practice a shot in the arm.

“The long-term health consequence of the COVID-19 pandemic are unknown but likely to be severe. That includes the effects of patients delaying or avoiding care, an increase in mental health concerns and the impacts of the virus itself on long-term physical and mental wellbeing.

“Primary care will be absolutely essential in managing the health of our communities in the months and years ahead but GPs need the right support to do so.

“Each year, GPs provide care to nearly 90% of Australians, yet general practice represents less than 13% of federal government health expenditure.

“This must change now because GPs provide the long-term care needed to improve the health trajectory of patients, keeping them well and out of hospital. The pandemic has placed an enormous strain on our healthcare system and led to many people suffering from poorer health outcomes – if we want to get on top of these problems we need to boost investment in primary care.”

Dr Willett said that the right investments would make an enormous difference for many patients.

“Many aspects of healthcare policy are complicated, but this is strikingly simple – a boost to primary care funding would allow more people to access quality care from their GP and lead to better health outcomes for patients as well as reduced healthcare expenditure.

“We have clearly laid out where government should provide greater support for general practice and improve patient health.

“During the pandemic many patients have avoided seeing their GP for new symptoms or serious existing conditions. Expanded telehealth and telephone consultations are proving crucial for many patients so we need flexible telehealth services to be widely available beyond 30 September this year.

“Ensuring patients have continuity of care with a usual GP is essential. It results in more patients addressing their health concerns at first instance before they become more severe and require secondary care.

“A voluntary patient enrolment system, where clinics receive additional payments for ‘enrolling’ a patient with a regular GP, would enhance comprehensive care for more patients and reduce hospitalisations for those who frequently visit GPs.

 

“The delay in rolling out this funding system is unfortunate because the patients who will benefit the most from voluntary patient enrolment are those most at risk of the COVID-19 virus. That includes older Australians and people with chronic disease.

“The pandemic has also put immense strain on many people and led to more patients experiencing mental health concerns. To help these people we need longer consultations so that GPs can take the time to talk through what our patients are experiencing and how we can help them.

“The health impats of the pandemic on the overall health of the population will be long-lasting and GPs on the frontline need all the help they can get. Our plan will provide them with the resources they need to do just that.”

The RACGP’s Vision for general practice and a sustainable healthcare system outlines how greater investment in primary care will reduce the need for more expensive secondary care and enhance the nation’s productivity through a healthier workforce. It will also promote health equity for demographic groups who disproportionately rely on secondary care including treatment in hospitals.[/vc_column_text][/vc_column][/vc_row]